MedTrace Logo

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

NCT05062005 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 447

Last updated 2021-09-30

No results posted yet for this study

Summary

This trial is a multi-center phase III clinical trial. The purpose of this trial is to explore whether concurrent chemoradiotherapy is not inferior to induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Conditions

  • Locally Advanced Nasopharyngeal Carcinoma

Interventions

DRUG

Induction Chemotherapy

Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.

DRUG

Concurrent Chemotherapy

Cisplatin 100 mg/m², Q3w.

RADIATION

Definitive Radiotherapy

For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2027-08-31
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062005 on ClinicalTrials.gov